These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38294999)

  • 21. The usefulness of noninvasive liver stiffness assessment using shear-wave elastography for predicting liver fibrosis in children.
    Lee S; Choi YH; Cho YJ; Lee SB; Cheon JE; Kim WS; Ko JS; Koh J; Kang GH
    BMC Med Imaging; 2021 Apr; 21(1):68. PubMed ID: 33845776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study.
    Israelsen M; Torp N; Johansen S; Hansen CD; Hansen ED; Thorhauge K; Hansen JK; Villesen I; Bech K; Wernberg C; Andersen P; Lindvig KP; Tsochatzis EA; Thiele M; Rinella ME; Krag A;
    Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):218-228. PubMed ID: 38218202
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatic inflammation and fibrosis are profiles related to mid-term mortality in biopsy-proven MASLD: A multicenter study in Japan.
    Tsutsumi T; Kawaguchi T; Fujii H; Kamada Y; Takahashi H; Kawanaka M; Sumida Y; Iwaki M; Hayashi H; Toyoda H; Oeda S; Hyogo H; Morishita A; Munekage K; Kawata K; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Tokushige A; Ueda S; Aishima S; Nakajima A; Okanoue T
    Aliment Pharmacol Ther; 2024 Jun; 59(12):1559-1570. PubMed ID: 38651312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. From NAFLD to MASLD: When metabolic comorbidity matters.
    Hong S; Sun L; Hao Y; Li P; Zhou Y; Liang X; Hu J; Wei H
    Ann Hepatol; 2024; 29(2):101281. PubMed ID: 38135250
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liver Stiffness Measurements by 2D Shear-Wave Elastography: Effect of Steatosis on Fibrosis Evaluation.
    Kumada T; Toyoda H; Yasuda S; Ogawa S; Gotoh T; Ito T; Tada T; Tanaka J
    AJR Am J Roentgenol; 2022 Oct; 219(4):604-612. PubMed ID: 35506556
    [No Abstract]   [Full Text] [Related]  

  • 26. MASLD, hepatic steatosis and fibrosis are associated with the prevalence of chronic kidney disease and retinopathy in adults with type 1 diabetes mellitus.
    Mantovani A; Morieri ML; Aldigeri R; Palmisano L; Masulli M; Bonomo K; Baroni MG; Cossu E; Cimini FA; Cavallo G; Buzzetti R; Mignogna C; Leonetti F; Bacci S; Trevisan R; Pollis RM; Cas AD; de Kreutzenberg SV; Targher G
    Diabetes Metab; 2024 Jan; 50(1):101497. PubMed ID: 37992857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence.
    Gao J; Li Y; Zhang Y; Zhan X; Tian X; Li J; Wang R; He Y; Wang A; Wu S
    J Am Heart Assoc; 2024 Mar; 13(5):e032604. PubMed ID: 38390843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolomic Phenotype of Hepatic Steatosis and Fibrosis in Mexican Children Living with Obesity.
    Garibay-Nieto N; Pedraza-Escudero K; Omaña-Guzmán I; Garcés-Hernández MJ; Villanueva-Ortega E; Flores-Torres M; Pérez-Hernández JL; León-Hernández M; Laresgoiti-Servitje E; Palacios-González B; López-Alvarenga JC; Lisker-Melman M; Vadillo-Ortega F
    Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893503
    [No Abstract]   [Full Text] [Related]  

  • 29. Optimizing surveillance of low-risk metabolic dysfunction associated steatotic liver disease using transient elastography.
    Gopalakrishna H; Nair GB; Salman Roghani R; Ravendhran N; Rotman Y
    Eur J Gastroenterol Hepatol; 2024 Apr; 36(4):476-481. PubMed ID: 38407839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the effects of pemafibrate on metabolic dysfunction-associated steatotic liver disease with hypertriglyceridemia using magnetic resonance elastography combined with fibrosis-4 index and the magnetic resonance imaging-aspartate aminotransferase score.
    Ichikawa T; Oba H; Owada M; Watanabe K; Yoshimura T; Fuchigami A; Nakamura A
    JGH Open; 2023 Dec; 7(12):959-965. PubMed ID: 38162848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.
    ; ;
    Diabetologia; 2024 Jun; ():. PubMed ID: 38869512
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings.
    Lee CM; Yoon EL; Kim M; Kang BK; Cho S; Nah EH; Jun DW
    Hepatology; 2024 Jun; 79(6):1393-1400. PubMed ID: 38100294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Poorly controlled pediatric type 1 diabetes mellitus is a risk factor for metabolic dysfunction associated steatotic liver disease (MASLD): An observational study.
    Koutny F; Wiemann D; Eckert A; Meyhöfer S; Fritsch M; Pappa A; Wiegand S; Weyer M; Wurm M; Weghuber D; Holl RW
    J Pediatr Gastroenterol Nutr; 2024 May; 78(5):1027-1037. PubMed ID: 38558281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glomerular Hyperfiltration: A Marker of Fibrosis Severity in Metabolic Associated Steatotic Liver Disease in an Adult Population.
    Dalbeni A; Garbin M; Zoncapè M; Romeo S; Cattazzo F; Mantovani A; Cespiati A; Fracanzani AL; Tsochatzis E; Sacerdoti D; Mantovani A; Lombardi R
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interactions between Metabolic Syndrome, MASLD, and Arterial Stiffening: A Single-Center Cross-Sectional Study.
    Solomon A; Negrea MO; Cipăian CR; Boicean A; Mihaila R; Rezi C; Cristinescu BA; Berghea-Neamtu CS; Popa ML; Teodoru M; Stoia O; Neamtu B
    Healthcare (Basel); 2023 Oct; 11(19):. PubMed ID: 37830733
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Severity of liver fibrosis using shear wave elastography is influenced by hepatic necroinflammation in chronic hepatitis patients, but not in cirrhotic patients.
    Nakano C; Nishimura T; Tada T; Yoshida M; Takashima T; Aizawa N; Ikeda N; Nishikawa H; Enomoto H; Hatano E; Yano H; Hirota S; Hachiya H; Iijima H
    Hepatol Res; 2021 Apr; 51(4):436-444. PubMed ID: 33462941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Shear wave elastography for liver fibrosis in chronic hepatitis B: Adapting the cut-offs to alanine aminotransferase levels improves accuracy.
    Zeng J; Zheng J; Jin JY; Mao YJ; Guo HY; Lu MD; Zheng HR; Zheng RQ
    Eur Radiol; 2019 Feb; 29(2):857-865. PubMed ID: 30039224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis.
    Burmeister Y; Weyer K; Dörre A; Seilheimer B
    Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease.
    Semmler G; Balcar L; Wernly S; Völkerer A; Semmler L; Hauptmann L; Wernly B; Aigner E; Niederseer D; Datz C
    Front Endocrinol (Lausanne); 2023; 14():1244405. PubMed ID: 37842290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alanine aminotransferase cutoffs for the pediatric fatty liver disease: Major impact of the reference population.
    Aitokari L; Lahti S; Kivelä L; Riekki H; Hiltunen P; Vuorela N; Viitasalo A; Soininen S; Huhtala H; Lakka T; Kurppa K
    J Pediatr Gastroenterol Nutr; 2024 Mar; 78(3):488-496. PubMed ID: 38314943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.